Haemonetics Corporation (NYSE:HAE) is a global healthcare company specializing in blood management solutions. It provides products and services for blood and plasma collection, processing, and transfusion. The company competes with other medical technology firms like Terumo and Fresenius. On August 7, 2025, Mike Matson from Needham set a price target of $68 for HAE, suggesting a potential upside of 22.21% from its trading price of $55.64.
Despite a 4.4% decline in revenue to $321 million for the quarter ending June 2025, Haemonetics exceeded Wall Street's expectations. The revenue surpassed the Zacks Consensus Estimate of $303 million by 5.97%. This indicates the company's ability to perform better than analysts' predictions, which is a positive sign for investors.
The company's earnings per share (EPS) for the quarter were $1.10, up from $1.02 the previous year. This improvement also beat the consensus estimate of $1.01 by 8.91%. Such performance metrics are crucial for investors as they reflect the company's financial health and potential for stock price growth.
Currently, HAE is trading at $55.63 on the NYSE, experiencing a significant decrease of -$20.14, or -26.58%. The stock has fluctuated between $55.32 and $72.15 today. Over the past year, it reached a high of $94.99 and a low of $55.30, indicating volatility in its market performance.
Haemonetics' market capitalization is approximately $2.67 billion, with a trading volume of 5,363,001 shares. These figures provide insight into the company's size and the level of investor interest. Despite recent challenges, the company's ability to exceed earnings expectations may attract investors looking for potential growth opportunities.
